Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 Axis

Journal of Immunology

Volumn 193, Issue 7, 2014, Pages 3278-3287

  Works, Melissa G ^a   Yin, Fangfang ^a   Yin, Catherine C ^a   Yiu, Ying ^a   Shew, Kenneth ^a   Tran, Thanh Thuy ^a   Dunlap, Nahoko ^a   Lam, Jennifer ^a   Mitchell, Tim ^a   Reader, John ^b   Stein, Paul L ^a   D'Andrea, Annalisa ^a  

^a SRI INTERNATIONAL   (United States)

^b Sareum Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN KINASE TYK2; SAR 20347; SERUM AMYLOID A; UNCLASSIFIED DRUG; IFNG PROTEIN, HUMAN; INTERLEUKIN 12; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; JAK1 PROTEIN, HUMAN; JAK1 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; TYK2 PROTEIN, HUMAN; TYK2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; IN VIVO STUDY; KERATINOCYTE; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PSORIASIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; MUTANT MOUSE STRAIN; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DERMATITIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKINS; JANUS KINASE 1; MICE; MICE, MUTANT STRAINS; PROTEIN KINASE INHIBITORS; PSORIASIS; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; TYK2 KINASE;

EID: 84907226117     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400205     Document Type: Article

References (35)

1. Wagner, E. F., H. B. Schonthaler, J. Guinea-Viniegra, and E. Tschachler. 2010. Psoriasis: what we have learned from mouse models. Nat. Rev. Rheumatol. 6: 704-714.
2. Cingoz, O. 2009. Ustekinumab. MAbs 1: 216-221.
3. Becher, B., and S. Pantelyushin. 201 2. Hiding under the skin: interleukin-17-producing gd T cells go under the skin? Nat. Med. 18: 1748-1750.
4. Boniface, K., E. Guignouard, N. Pedretti, M. Garcia, A. Delwail, F. X. Bernard, F. Nau, G. Guillet, G. Dagregorio, H. Yssel, et al. 2007. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin. Exp. Immunol. 150: 407-415.
5. Sonnenberg, G. F., L. A. Fouser, and D. Artis. 2011. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12: 383-390.
6. W olk, K., H. S. Haugen, W. Xu, E. Witte, K. Waggie, M. Anderson, E. Vom Baur, K. Witte, K. Warszawska, S. Philipp, et al. 2009. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis whi le IL-17 and IFN-gamma are not. J. Mol. Med. 87: 523-536.
7. Gedebjerg, A., C. Johansen, K. Kragballe, and L. Iversen. 2013. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta Derm. Venereol. 93: 150-155.
8. Michalak-Stoma, A., J. Bartosi-nska, M. Kowal, M. Juszkiewicz-Borowiec, A. Gerkowicz, and G. Chodorowska. 2013. Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis. Markers 35: 625-631.
9. Sohn, S. J., K. Barrett, A. Van Abbema, C. Chang, P. B. Kohli, H. Kanda, J. Smith, Y. Lai, A. Zhou, B. Zhang, et al. 201 3. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J. Immunol. 191: 2205-2216.
10. Ishizaki, M., T. Akimoto, R. Muromoto, M. Yokoyama, Y. Ohshiro, Y. Sekine, H. Maeda, K. Shimoda, K. Oritani, and T. Matsuda. 2011. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J. Immunol. 187: 181-189.
11. Strange A.,F. Capon,C.C. Spencer,J. Knight,M.E. Weale,M.H. Allen,A. Barton,G. Band,C. Bellenguez,J.G. Bergboer,et al; Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2. 2010. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 42:985-990.
12. Tsoi, L. C., S. L. Spain, J. Knight, E. Ellinghaus, P. E. Stuart, F. Capon, J. Ding, Y. Li, T. Tejasvi, J. E. Gudjonsson, et al; Collaborative Association Study of Psoriasis (CASP).; Genetic Analysis of Psoriasis Consortium.; Psoriasis Association Genetics Ext e nsion.; Wellcome Trust Case Control Consortium 2. 2012. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 44: 1341-1348.
13. Strobl, B., D. Stoiber, V. Sexl, and M. Mueller. 2011. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front. Biosci. (Landmark Ed.) 16: 3214-3232.
14. Spach, K. M., R. Noubade, B. McElvany, W. F. Hickey, E. P. Blankenhorn, and C. Teuscher. 2009. A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis. J. Immunol. 182: 7776-7783.
15. Van Rompaey, L., R. Galien, E. M. van der Aar, P. Clement-Lacroix, L. Nelles, B. Smets, L. Lepescheux, T. Christophe, K. Conrath, N. Vandeghinste, et al. 2013. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J. Immunol. 191: 3568-3577.
16. van der Fits, L., S. Mourits, J. S. Voerman, M. Kant, L. Boon, J. D. Laman, F. Cornelissen, A. M. Mus, E. Florencia, E. P. Prens, and E. Lubberts. 2009. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182: 5836-5845.
17. Liang, J., V. Tsui, A. Van Abbema, L. Bao, K. Barrett, M. Beresini, L. Berezhkovskiy, W. S. Blair, C. Chang, J. Driscoll, et al. 2013. Lead identification of novel and selective TYK2 inhibitors. Eur. J. Med. Chem. 67: 175-187.
18. Yu, V., J. Pistillo, I. Archibeque, J. Han Lee, B. C. Sun, L. B. Schenkel, S. Geuns-Meyer, L. Liu, and R. Emkey. 2013. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings. Exp. Hematol. 41: 491-500.
19. Shaw, M. H., V. Boyartchuk, S. Wong, M. Karaghiosoff, J. Ragimbeau, S. Pellegrini, M. Muller, W. F. Dietrich, and G. S. Yap. 2003. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc. Natl. Acad. Sci. USA 100: 11594-11599.
20. Ghoreschi, K., A. Laurence, and J. J. O'Shea. 2009. Janus kinases in immune cell signaling. Immunol. Rev. 228: 273-287.
21. Liang, J., A. van Abbema, M. Balazs, K. Barrett, L. Berezhkovsky, W. B lair, C. Chang, D. Delarosa, J. DeVoss, J. Driscoll, et al. 2013. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J. Med. Chem. 56: 4521 -4536.
22. Liang, S. C., C. Nickerson-Nutter, D. D. Pittman, Y. Carrier, D. G. Goodwin, K. M. Shields, A. J. Lambert, S. H. Schelling, Q. G. Medley, H. L. Ma, et al. 2010. IL-22 induces an acute-phase response. J. Immunol. 185: 5531-5538.
23. Johnson-Huang, L. M., M. A. Lowes, and J. G. Krueger. 2012. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis. Model. Mech. 5: 423-433.
24. van den Berg, W. B., and I. B. McInnes. 2013. Th17 cells and IL-17a-focus on immunopathogenesis and immunotherapeutics. Semin. Arthritis Rheum. 43: 158-170.
25. Di Cesare, A., P. Di Meglio, and F. O. Nestle. 2009. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 129: 1339-1350.
26. Grossman, R. M., J. Krueger, D. Yourish, A. Granelli-Piperno, D. P. Murphy, L. T. May, T. S. Kupper, P. B. Sehgal, and A. B. Gottlieb. 1989. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human ker atinocytes. Proc. Natl. Acad. Sci. USA 86: 6367-6371.
27. Lindroos, J., L. Svensson, H. Norsgaard, P. Lovato, K. Moller, P. H. Hagedorn, G. M. Olsen, and T. Labuda. 2011. IL-23-mediated epidermal hyperplasia is dependent on IL-6. J. Invest. Dermatol. 131: 1110-1118.
28. Ueyama, A., M. Yamamoto, K. Tsujii, Y. Furue, C. Imura, M. Shichijo, and K. Yasui. 2014. Mechanism of pathoge nesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod. J. Dermatol. 41: 135-143.
29. Tokumasa, N., A. Suto, S. Kagami, S. Furuta, K. Hirose, N. Watanabe, Y. Saito, K. Shimoda, I. Iwamoto, and H. Nakajima. 2007. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood 110: 553-560.
30. Noack, M., and P. Miossec. 2014. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun. Rev. 13: 668-677.
31. Cai, Y., X. Shen, C. Ding, C. Qi, K. Li, X. Li, V. R. Jala, H. G. Zhang, T. Wang, J. Zheng, and J. Yan. 2011. Pivotal role of dermal IL-17-producing gd T cells in skin inflammation. Immunity 35: 596-610.
32. Van Belle, A. B., M. de Heusch, M. M. Lemaire, E. Hendrickx, G. Warnier, K. Dunussi-Joannopoulos, L. A. Fouser, J. C. Renauld, and L. Dumoutier. 2012. IL-22 is required for imiquimod-induced pso riasiform skin inflammation in mice. J. Immunol. 188: 462-469.
33. Ma, H. L., S. Liang, J. Li, L. Napierata, T. Brown, S. Benoit, M. Senices, D. Gi ll, K. Dunussi-Joannopoulos, M. Collins, et al. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 118: 597-607.
34. Wolk, K., E. Witte, K. Witte, K. Warszawska, and R. Sabat. 2010. Biology of interleukin-22. Semin. Immunopathol. 32: 17-31.
35. Simmons, D. L. 2013. Targeting kinases: a new approach to treating inflammatory rheumatic diseases. Curr. Opin. Pharmacol. 13: 426-434.